PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1174974
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1174974
According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 0.32 billion by 2032 with a CAGR of 3.68%.
The varicella-zoster virus is the cause of the viral illness known as herpes zoster (shingles). It often starts as a burning, itchy skin rash that spreads to the rest of the body, causing blisters on the back, chest, and face. Pain along the afflicted dermatome is usually the first symptom, which is followed in 2-3 days by an expanded vesicular eruption. Lymph nodes, fever, chills, and headache are among the symptoms. There may also be itching, raised spots on the skin, localised redness, a stabbing or shooting pain, tingling or burning sensation in or beneath the skin, or an upset stomach.
In order to prevent cross-contamination, fewer procedures and patients have visited hospitals. This has a detrimental effect on the market for herpes zoster medications. Additionally, a reduction in staff was made to care for patients receiving herpes zoster therapy as a result of the transfer in medical personnel to treat COVID-19-infected individuals. As a result, non-elective procedures were delayed at several hospitals and healthcare institutes. The market for herpes zoster medications, however, is anticipated to gradually rebound after the epidemic.